EligibleTrials
Drugs & treatments › Vinorelbine

Vinorelbine: clinical trials recruiting now

9
Recruiting trials
13
Conditions studied
24
US states with sites
20
Countries

FDA drug label

FDA-approved
Yes. Vinorelbine appears in the FDA drug-label database. Marketed as Vinorelbine.
Boxed warning
The FDA label for Vinorelbine carries a boxed warning (the FDA's most serious warning). See the full label for details.

FDA-approved use

Vinorelbine Injection is indicated: In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) As a single agent for the treatment of patients with metastatic NSCLC Vinorelbine Injection is a vinca alkaloid indicated: In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) ( 1 ) As a single agent for first-line treatment of patients with metastatic NSCLC ( 1 )

FDA label via openFDA

Phase breakdown

Phase 2 2 Phase 3 6 Not applicable 1

Conditions being studied

ConditionTrials
Breast Cancer · Vinorelbine for Breast Cancer6
Lung cancer · Vinorelbine for Lung cancer3
Advanced Breast Cancer1
Advanced Non Small Cell Lung Cancer1
Breast Cancer, Metastatic1
Carcinoma, Non-Small -Cell Lung1
HER2-negative Breast Cancer1
Locally Advanced or Metastatic Breast Cancer1
MET Exon 14 Mutation1
Metastatic Breast Cancer1
Metastatic HER2-positive Breast Cancer1
NSCLC1
Refractory Breast Carcinoma1

Recruiting trials involving Vinorelbine

Common questions

Is Vinorelbine FDA-approved?

Yes, marketed as Vinorelbine. Its FDA label carries a boxed warning.

How many recruiting trials involve Vinorelbine?

9 recruiting trials across 13 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.